BRAF Kinase Inhibitors Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, France, Japan - Size and Forecast 2024-2028

Published: Dec 2023 Pages: 162 SKU: IRTNTR73550

BRAF Kinase Inhibitors Market 2024-2028

The global BRAF kinase inhibitors market size is estimated to grow by USD 1.40 billion at a CAGR of 7.88% between 2023 and 2028. 

Prominent drugs based on BRAF kinase inhibitors, such as dabrafenib and sorafenib, are revolutionizing the therapeutic strategies of HCC, RCC, NSCLC, and melanomas. However, the high costs of these drugs remain a challenge to patients as well as the healthcare system. To overcome this challenge, many government and non-government organizations, including pharmaceutical companies, are focusing on providing financial assistance and clinical assistance for the treatment of various cancer indications. Such patient-assistance programs encourage more patients to avail the required treatment, resulting in a wider patient base. This also helps them adhere to the treatment regimen even if it goes into a long-term tenure, which will drive the growth of the market during the forecast period.

Technavio has segmented the market into Product, Distribution Channel, and Geography 

  • The product segment includes dabrafenib, sorafenib, vemurafenib, and encorafenib
  • The distribution channel segment includes hospital pharmacies, retail pharmacies, and online pharmacies
  • The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2018-2022, besides analyzing the current market scenario.

What will be the size of the BRAF Kinase Inhibitors Market During the Forecast Period?

To learn more about this report, Download Report Sample

BRAF Kinase Inhibitors Market Segmentation by Product, Distribution Channel, and Geography 

Product Analysis 

Dabrafenib

The market share growth by the dabrafenib segment will be significant during the forecast period. Dabrafenib is an orally administered drug sold under the brand name TAFINLAR for the treatment of cancers associated with a mutated BRAF gene. Dabrafenib acts as an inhibitor of the associated BRAF enzyme, which plays a crucial role in the regulation of cell growth. Dabrafenib has clinical activity, with a manageable safety and efficacy profile demonstrated across various clinical trials in patients with BRAF(V600)-mutated metastatic melanoma. 

Get a glance at the market contribution of various segments Download PDF Sample

The dabrafenib segment was valued at USD 1.08 billion in 2018. The growth of this segment is primarily driven by the high prevalence of lung cancer, as dabrafenib (TAFINLAR) is the only BRAF inhibitor approved for the treatment of NSCLC with BRAF V600E mutation. The high prevalence of BRAF melanoma is a key factor that drives the growth of this segment. Another combination that has been approved recently is BRAFTOVI (encorafenib) and MEKTOVI (binimetinib). This approval is expected to pose a challenge to the growth of this segment during the forecast period.

Distribution Channel Analysis

Hospital pharmacies

Hospital pharmacies are departments within hospitals that prepare, compound, stock, and dispense inpatient drugs. In most cases, hospital management leases space to private vendors that operate their private pharmacies. Hospital pharmacy staffing requirements vary depending on workload and hospital number of beds. In small hospitals, at least three pharmacists are required. Increasing numbers of hospitals globally, and hospitals play an important role in patient education and support, therefore increasing the demand for hospital pharmacy services, which is expected to propel the growth of the hospital pharmacies segment in the global BRAF kinase inhibitors market during the forecast period.

Retail pharmacies

Retail pharmacists consult and guide patients through symptoms and provide guidance to prevent adverse reactions and drug-drug interactions. A retail or community pharmacy is an independent or chain pharmacy that is licensed by the State as a pharmacy and sells medications to the public at a retail price. Retail pharmacies are usually located throughout the community for easy access. Furthermore, an increasing number of retail pharmacies are expected to boost the growth of the retail pharmacies segment in the global BRAF kinase inhibitors market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The growth of the market in this region is primarily driven by the sales of approved BRAF kinase inhibitors and the increasing prevalence of several cancer indications, including RCC, melanomas, and NSCLC, in the region. Furthermore, BRAF kinase inhibitors are attracting substantial R&D attention in the country due to their proven efficacy and target-specific treatment approach. These extensive R&D efforts get further support from established R&D platforms and major oncology vendors in the country, resulting in a substantial drug development pipeline. Thus, such drug development designations and the expansion of research areas of approved drugs for other indications are expected to support the growth of the market in the region during the forecast period.

Buy Full Report Now

Key BRAF Kinase Inhibitors Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 13 market companies, including:

Asana BioSciences LLC: The company offers BRAF kinase inhibitors such as ASN003, a highly selective inhibitor of BRAF and PI3K kinases. ASN003 is a potent and highly selective inhibitor of BRAF and PI3 pha and delta kinases.

  • Bayer AG
  • BeiGene Ltd.
  • F. Hoffmann La Roche Ltd.
  • Fore Biotherapeutics Inc.
  • Jazz Pharmaceuticals Plc
  • Nerviano Medical Sciences S.r.l
  • Novartis AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Pierre Fabre SA
  • Kinnate Biopharma
  • Black Diamond Therapeutics Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

BRAF Kinase Inhibitors Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key BRAF Kinase Inhibitors Market Drivers

The increasing prevalence of cancer is the key factor driving market growth. The prevalence of cancer has seen a significant rise in recent years globally, and the global pharmaceuticals market has witnessed the approval of various novel therapies, especially in the field of oncology. The gap between the demand and supply of these therapies has resulted in a huge unmet need, which has created an opportunity for market players to conduct studies on target-specific drugs.

In addition, the new cases of cancer has increased significantly in recent years, owing to factors such as the increasing geriatric population and lifestyle changes. It is estimated that 38.4% of all adults in the US will develop cancer during their lifetime. With the increasing prevalence of cancer, the demand for BRAF kinase-inhibiting drugs is also increasing, which will propel the growth of the market during the forecast period.

Significant BRAF Kinase Inhibitors Market Trends

Expansion of research areas in BRAF kinase inhibitors is the primary trend shaping market growth. BRAF kinase inhibitors have demonstrated efficacy in several oncology indications, such as NSCLC, melanomas, and RCC, and several vendors are seeking to expand the clinical reach of these drugs further. Currently, four BRAF kinase inhibitors are approved for the treatment of various cancer types.

 However, owing to their high target affinity and specificity, many companies are researching the treatment of more than three different types of cancers using BRAF kinase inhibitors. Similarly, about 50 clinical trials are being carried out by various companies for different types of cancers. Such expansions in the research areas of BRAF kinase inhibitors will have a substantial impact on the market during the forecast period.

Major BRAF Kinase Inhibitors Market Challenges

Increasing awareness about the adverse effects of available drugs is a challenge that affects market growth. The treatment landscape of oncology indications, including NSCLC, melanomas, and RCC, is developing at a very fast rate. However, BRAF kinase inhibitor therapeutics demonstrate a range of adverse effects, such as fatigue, muscle cramps, nausea, vomiting, and diarrhea. Some of the rare events include low blood counts, edema, congestive heart failure, and severe liver problems.

Moreover, the combination of BRAF kinase inhibitors and radiation therapy often leads to cytotoxic effects and myelosuppression. Despite being highly efficacious, the BRAF kinase inhibitors used for treating some oncology indications are associated with a spectrum of side effects. These side effects limit patient adherence to treatments, which will impede the growth of the market during the forecast period.

Buy Now Full Report

Key BRAF Kinase Inhibitors Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global BRAF Kinase Inhibitors Market Customer Landscape

Segment Overview

The BRAF kinase inhibitors market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

  • Product Outlook
    • Dabrafenib
    • Sorafenib
    • Vemurafenib
    • Encorafenib
  • Distribution Channel Outlook
    • Hospital pharmacies
    • Retail pharmacies
    • Online pharmacies
  • Region Outlook
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of the World (ROW)
      • Brazil 
      • Argentina
      • Australia

BRAF Kinase Inhibitors Market Scope

Report Coverage

Details

Page number

162

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 7.88%

Market Growth 2024-2028

USD 1.40 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

7.15

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 41%

Key countries

US, Germany, UK, France, and Japan

Competitive landscape

 Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

Asana BioSciences LLC, Bayer AG, BeiGene Ltd., F. Hoffmann La Roche Ltd., Fore Biotherapeutics Inc., Jazz Pharmaceuticals Plc, Nerviano Medical Sciences S.r.l, Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Pierre Fabre SA, Kinnate Biopharma, and Black Diamond Therapeutics Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. 

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this BRAF Kinase Inhibitors Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the BRAF kinase inhibitors market between 2024 and 2028
  • Precise estimation of the size of the BRAF kinase inhibitors market size and its contribution to the market in focus on the parent market
  • Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies' position and classification
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of BRAF kinase inhibitors market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global BRAF kinase inhibitors market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global braf kinase inhibitors market 2018 - 2022 ($ billion)
    • 4.2 Product Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Product Segment 2018 - 2022 ($ billion)
    • 4.3 Type Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Type Segment 2018 - 2022 ($ billion)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Product

    • 6.1 Market segments
      • Exhibit 30: Chart on Product - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
    • 6.2 Comparison by Product
      • Exhibit 32: Chart on Comparison by Product
      • Exhibit 33: Data Table on Comparison by Product
    • 6.3 Dabrafenib - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Dabrafenib - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 35: Data Table on Dabrafenib - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 36: Chart on Dabrafenib - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Dabrafenib - Year-over-year growth 2023-2028 (%)
    • 6.4 Sorafenib - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Sorafenib - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 39: Data Table on Sorafenib - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 40: Chart on Sorafenib - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Sorafenib - Year-over-year growth 2023-2028 (%)
    • 6.5 Vemurafenib - Market size and forecast 2023-2028
      • Exhibit 42: Chart on Vemurafenib - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 43: Data Table on Vemurafenib - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 44: Chart on Vemurafenib - Year-over-year growth 2023-2028 (%)
      • Exhibit 45: Data Table on Vemurafenib - Year-over-year growth 2023-2028 (%)
    • 6.6 Encorafenib - Market size and forecast 2023-2028
      • Exhibit 46: Chart on Encorafenib - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 47: Data Table on Encorafenib - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 48: Chart on Encorafenib - Year-over-year growth 2023-2028 (%)
      • Exhibit 49: Data Table on Encorafenib - Year-over-year growth 2023-2028 (%)
    • 6.7 Market opportunity by Product
      • Exhibit 50: Market opportunity by Product ($ billion)
      • Exhibit 51: Data Table on Market opportunity by Product ($ billion)

    7 Market Segmentation by Distribution Channel

    • 7.1 Market segments
      • Exhibit 52: Chart on Distribution Channel - Market share 2023-2028 (%)
      • Exhibit 53: Data Table on Distribution Channel - Market share 2023-2028 (%)
    • 7.2 Comparison by Distribution Channel
      • Exhibit 54: Chart on Comparison by Distribution Channel
      • Exhibit 55: Data Table on Comparison by Distribution Channel
    • 7.3 Hospital pharmacies - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 57: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 58: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
    • 7.4 Retail pharmacies - Market size and forecast 2023-2028
      • Exhibit 60: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 61: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 62: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 63: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
    • 7.5 Online pharmacies - Market size and forecast 2023-2028
      • Exhibit 64: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 65: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 66: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 67: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
    • 7.6 Market opportunity by Distribution Channel
      • Exhibit 68: Market opportunity by Distribution Channel ($ billion)
      • Exhibit 69: Data Table on Market opportunity by Distribution Channel ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 71: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 72: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 73: Chart on Geographic comparison
      • Exhibit 74: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 Germany - Market size and forecast 2023-2028
      • Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.9 UK - Market size and forecast 2023-2028
      • Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.10 France - Market size and forecast 2023-2028
      • Exhibit 103: Chart on France - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 104: Data Table on France - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 105: Chart on France - Year-over-year growth 2023-2028 (%)
      • Exhibit 106: Data Table on France - Year-over-year growth 2023-2028 (%)
    • 9.11 Japan - Market size and forecast 2023-2028
      • Exhibit 107: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 108: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 109: Chart on Japan - Year-over-year growth 2023-2028 (%)
      • Exhibit 110: Data Table on Japan - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 111: Market opportunity by geography ($ billion)
      • Exhibit 112: Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 113: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 115: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 116: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 117: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 118: Matrix on vendor position and classification
            • 12.3 Asana BioSciences LLC
              • Exhibit 119: Asana BioSciences LLC - Overview
              • Exhibit 120: Asana BioSciences LLC - Product / Service
              • Exhibit 121: Asana BioSciences LLC - Key offerings
            • 12.4 Bayer AG
              • Exhibit 122: Bayer AG - Overview
              • Exhibit 123: Bayer AG - Business segments
              • Exhibit 124: Bayer AG - Key news
              • Exhibit 125: Bayer AG - Key offerings
              • Exhibit 126: Bayer AG - Segment focus
            • 12.5 BeiGene Ltd.
              • Exhibit 127: BeiGene Ltd. - Overview
              • Exhibit 128: BeiGene Ltd. - Business segments
              • Exhibit 129: BeiGene Ltd. - Key offerings
              • Exhibit 130: BeiGene Ltd. - Segment focus
            • 12.6 Black Diamond Therapeutics Inc.
              • Exhibit 131: Black Diamond Therapeutics Inc. - Overview
              • Exhibit 132: Black Diamond Therapeutics Inc. - Product / Service
              • Exhibit 133: Black Diamond Therapeutics Inc. - Key offerings
            • 12.7 F. Hoffmann La Roche Ltd.
              • Exhibit 134: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 135: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 136: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 137: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 138: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.8 Fore Biotherapeutics Inc.
              • Exhibit 139: Fore Biotherapeutics Inc. - Overview
              • Exhibit 140: Fore Biotherapeutics Inc. - Product / Service
              • Exhibit 141: Fore Biotherapeutics Inc. - Key offerings
            • 12.9 Jazz Pharmaceuticals Plc
              • Exhibit 142: Jazz Pharmaceuticals Plc - Overview
              • Exhibit 143: Jazz Pharmaceuticals Plc - Product / Service
              • Exhibit 144: Jazz Pharmaceuticals Plc - Key news
              • Exhibit 145: Jazz Pharmaceuticals Plc - Key offerings
            • 12.10 Kinnate Biopharma
              • Exhibit 146: Kinnate Biopharma - Overview
              • Exhibit 147: Kinnate Biopharma - Product / Service
              • Exhibit 148: Kinnate Biopharma - Key offerings
            • 12.11 Nerviano Medical Sciences S.r.l
              • Exhibit 149: Nerviano Medical Sciences S.r.l - Overview
              • Exhibit 150: Nerviano Medical Sciences S.r.l - Product / Service
              • Exhibit 151: Nerviano Medical Sciences S.r.l - Key offerings
            • 12.12 Novartis AG
              • Exhibit 152: Novartis AG - Overview
              • Exhibit 153: Novartis AG - Business segments
              • Exhibit 154: Novartis AG - Key offerings
              • Exhibit 155: Novartis AG - Segment focus
            • 12.13 Ono Pharmaceutical Co. Ltd.
              • Exhibit 156: Ono Pharmaceutical Co. Ltd. - Overview
              • Exhibit 157: Ono Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 158: Ono Pharmaceutical Co. Ltd. - Key offerings
            • 12.14 Pfizer Inc.
              • Exhibit 159: Pfizer Inc. - Overview
              • Exhibit 160: Pfizer Inc. - Product / Service
              • Exhibit 161: Pfizer Inc. - Key news
              • Exhibit 162: Pfizer Inc. - Key offerings
            • 12.15 Pierre Fabre SA
              • Exhibit 163: Pierre Fabre SA - Overview
              • Exhibit 164: Pierre Fabre SA - Business segments
              • Exhibit 165: Pierre Fabre SA - Key offerings
              • Exhibit 166: Pierre Fabre SA - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 167: Inclusions checklist
                • Exhibit 168: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 169: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 170: Research methodology
                • Exhibit 171: Validation techniques employed for market sizing
                • Exhibit 172: Information sources
              • 13.5 List of abbreviations
                • Exhibit 173: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              braf kinase inhibitors market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis